. Author manuscript; available in PMC: 2021 Aug 2.

Published in final edited form as: Clin Exp Ophthalmol. 2019 Dec 6;48(2):230–239. doi: 10.1111/ceo.13687

Table 1:

Patient, medication history, subjective responses and scale results

		Delta-9-THC (Dronabinol)¹²			THC & CBD³					CBD^14,15	Nabilone¹³
Patient characteristics	Condition	Blepharospasm			Blepharospasm	Blepharospasm	Blepharospasm	Blepharospasm	Blepharospasm	Meige syndrome	Primary dystonia (15 patients)
	Age	56			60	54	61	72	60	42	28 to 63
	Sex	Female			Female	Male	Female	Male	Female	Male	6 males, 9 females
Daily dose prescribed		1^st script: 10 mg	2^nd script: 30 mg	3^rd script: 10-5-15mg paradigm	5 mg THC, 95 mg CBD	10 mg THC, 10 mg CBD	1^st script: 5 mg THC, 5 mg CBD 2^nd script: 4 mg THC, 1 mg CBD	1^st script: 5 mg THC 2^nd script: 8 mg THC, 2 mg CBD	Up to 10 mg THC, 10 mg CBD	300/400 mg	** Single dose: 0.03 mg/kg to the nearest whole mg
Duration of cannabis use		Total duration: 16 weeks			8 weeks	2 weeks	12 weeks	12 weeks	8 weeks	6 weeks	NA
Duration of cannabis use		Over 2 weeks	After 5 weeks, clinical stable state reached		8 weeks	2 weeks	12 weeks	12 weeks	8 weeks	6 weeks	NA
Side effects		None	Vertigo	Reduction of vertigo	None	Sleep disturbance	Sleep disturbance	Sporadic headaches	Lightheadedness	Hypotension Dry Mouth Lightheadedness	2/15 patients: hypotension and pronounced sedation
Subjective Symptomatic Improvement (Yes/No)		No	Yes		Yes	NA: Patient discontinued the treatment after two weeks.	Yes	No	Yes	Yes	No: 4/15 patients experienced subjective improvement 2–3 days after administration
Symptom Score^a		NRS: 8.5–10	NRS: 3–5		Pre BSDIS: 3 BSDIF: 3 JRF: 10	NA	Pre BSDIS: 3 BSDIF: 3 JRF: 14	Pre BSDIS: 4 BSDIF: 4 JRF: 13	NA	Baseline DS: 29 Max. DS: 120 Maximal improvement: 40%	Median total movement DSs over 180 min placebo: • 70.5 (range, 11–216) for nabilone • 81 (range, 8–209) for placebo
Symptom Score^a		NRS: 8.5–10	NRS: 3–5		Post BSDIS: 2 BSDIF: 1 JRF: 6	NA	Post BSDIS: 2 BSDIF: 3 JRF: 12	Post BSDIS: 4 BSDIF: 4 JRF: 8	NA	Baseline DS: 29 Max. DS: 120 Maximal improvement: 40%
Reason for discontinuation		NA			Costs	Success of botulinum therapy	NA	No improvement noted	ER admission twice due to lightheadedness	NA	2/15 patients withdrawn due to side effects

Abbreviations of the symptom score scales

• NRS: Numerical Rating Scale (0–10)

• BSDIS: Blepharospasm Disability Index Severity (0–4)

• BSDIF: Blepharospasm Disability Index Frequency (0–4)

• JRS: Jankovic Rating Scale (0–24)

• DS: Dystonia Score following the Burke, Fahn, Marsden dystonia scale

• Pre: Pre-cannabis therapy blepharospasm scale results

• Post: Post-cannabis therapy blepharospasm scale results